Generate a tailored SOP for Dr. Caner Saygin. Improve your application with a focused, well-structured draft.
Dr. Saygin’s laboratory investigates the biology of leukemia using in vitro and in vivo models of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), as well as human patient samples. A key focus of the lab is understanding the drivers of clonal hematopoiesis of indeterminate potential (CHIP) and its progression in leukemias of myeloid and lymphoid lineage, particularly in de novo and therapy-related contexts. The overarching goal of Dr. Saygin’s translational research program is to identify the molecular and cellular mechanisms that drive these fatal diseases and to translate insights into novel therapeutic strategies. The lab’s drug development efforts, particularly focused on high-risk subsets of AML, have resulted in launching investigator-initiated phase I/II clinical trials that originate directly from discoveries made in the lab.
Department of Philosophy